Year None20242023202220212020 Dec 09, 2024 Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting Nov 07, 2024 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 Nov 05, 2024 Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting Oct 31, 2024 Lyell Immunopharma Completes Acquisition of ImmPACT Bio Oct 24, 2024 Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies Oct 04, 2024 Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting Sep 24, 2024 Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day Aug 28, 2024 Lyell Immunopharma Announces Participation in September Investor Conferences Aug 07, 2024 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 Jun 26, 2024 Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
